An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant
{{output}}
Rolapitant, a selective and long-acting neurokinin-1 receptor antagonist, is approved in an oral formulation for prevention of delayed chemotherapy-induced nausea and vomiting in adults. This pivotal open-label, randomized, single-dose, multicenter, parallel-g... ...
